Tesamorelin, also marketed under the trade name Egrifta, is known as and compared to a synthetic version of human growth hormone-releasing hormone (GHR), which stimulates and initiates the synthesis of endogenous growth hormone . Moreover, tesamorelin is a treatment used for reducing excess abdominal fat in HIV patients who have associated lipodystrophy . Growth hormone (GH) interacts with a variety of cell-specific receptors which go on to influence a range of pharmacodynamic effects in cells .
Figure 1. Structure of tesamorelin. Tesamorelin binds and stimulates the human growth-hormone-releasing (GRF) receptor in a similar manner to endogenous GRF. The pharmaceutical drug Egrifta (which cinatins tesamorelin) is exclusive to reduce excess abdominal fat in HIV-infected patients who suffer from lipo-dystrophy . Tesamorelin has shown stability in human and dog plasma.
How it works
In humans, growth hormone (GH) interacts with certain, specific receptors on cell surfaces. One of the more well-known effects of GH is its role in height growth during childhood via the stimulation of skeletal growth . However, GH has many other important cellular functions including, the regulation and modulation protein, lipid and carbohydrate metabolism . In this regard, deficiencies in GH can lead to more long-term problems and complications across different ages. In children, GH deficiency is characterised by short stature; in adults, GH deficiency is less obvious and can include, excessive body fat, a low bone mineral content, abnormalities in lipids (fats) and also a decrease in insulin sensitivity .